Case Studies

2024-11-05

Bacillus subtilis Expression: Secreted & Intracellular Protein Case Studies | AtaGenix

Two B. subtilis WB800N expression case studies from AtaGenix. Case 1: Secreted Protein A (~85 kDa) via pHT43 vector achieved 20 mg/L yield at >90% purity — protein directed into culture supernatant without cell lysis. Case 2: Intracellular Protein B (~42 kDa) via pHT254 achieved >95% purity at 1 mg/L. Both leveraged the endotoxin-free, GRAS-designated B. subtilis host, demonstrating AtaGenix's flexibility in prokaryotic expression beyond E. coli.

2024-11-05

HLA-I pMHC Tetramer: From E. coli Expression to T-Cell Detection Reagent | AtaGenix

AtaGenix produced custom pMHC tetramers from scratch: HLA-I heavy chain and β2M expressed in E. coli, refolded with target peptide into stable ternary complexes, site-specifically biotinylated via BirA, and assembled with streptavidin into SEC-verified tetramers. The client confirmed functional CD8+ T-cell staining by flow cytometry — demonstrating AtaGenix's end-to-end MHC-peptide complex platform for custom alleles and epitopes not available commercially.

2024-11-05

E. coli Expression Optimization: Solubility, Periplasmic Folding & Inclusion Body Refolding | AtaGenix

Three E. coli expression case studies from AtaGenix. Case 1: Systematic 32-condition optimization (4 strains × temperature × media) shifted an insoluble target to soluble expression, followed by 3C protease His-tag removal for crystallography. Case 2: Periplasmic expression rescued a disulfide-bonded antibody fragment — correctly folded with intact S–S bonds, no refolding required. Case 3: Gradient dialysis refolding recovered enzymatically active protein from obligate inclusion bodies. Together, these cases demonstrate AtaGenix's ability to exhaust the full E. coli toolkit before escalating to costlier eukaryotic systems.

2024-11-05

Antibody Gene Sequencing and Validation Case Study | AtaGenix Custom Antibody Development

Hybridoma sequencing enables the precise identification of heavy and light chain variable regions of monoclonal antibodies. The data includes high-quality PCR amplification, colony validation gels, and sequencing results, ensuring accuracy in gene identification and antibody production.

2024-11-04

Recombinant Antibody Expression & Functional QC Validation | AtaGenix

AtaGenix's recombinant antibody expression pipeline delivers assay-grade antibody from sequence to validated reagent. This case demonstrates the full QC workflow: SDS-PAGE (reducing + non-reducing) confirming correct HC/LC assembly and purity, SEC-HPLC verifying monomer content, endotoxin testing by LAL, and functional validation confirming antigen-specific binding. Every batch ships with dual verification — purity and function — ensuring the antibody works in the client's downstream application on the first attempt.

2024-11-04

Xten™ Mab Single B Rabbit Monoclonal Antibody Development Case Study

Using rabbit single B-cell antibody technology, an Anti-human CD86 rabbit monoclonal antibody was developed. Rabbits with serum titers greater than 128K were selected, and PBMCs were isolated for flow sorting to obtain human CD86 antigen-specific B-cell plates.

2024-11-04

SARS-CoV-2 Spike Protein: From Sequence to Assay-Grade Antigen in 18 Days | AtaGenix

A diagnostics partner needed assay-grade SARS-CoV-2 spike protein with native glycosylation. AtaGenix delivered >95% purity trimeric protein via HEK293 transient expression in 18 days — achieving 3.5x ELISA signal improvement over E. coli-derived RBD and enabling rapid serological kit validation.

2024-10-21

XtenCHO™ High-Density Expression: 500–1,500 mg/L Antibody Yields in Transient Timelines | AtaGenix

AtaGenix's proprietary XtenCHO™ platform benchmarked across 11 therapeutic antibodies: median yields 500–1,000 mg/L, top performer ~1,500 mg/L, with near-100% CHO cell viability sustained over 15-day cultures. XtenCHO™ bridges the gap between standard transient expression (100–300 mg/L, 5–7 days) and stable cell lines (12+ weeks development) — delivering stable-line-level yields in transient timelines for preclinical material generation and multi-candidate parallel evaluation.